Trevi Therapeutics (TRVI) Total Liabilities (2018 - 2026)

Trevi Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 0.9% year-over-year to $7.5 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 0.9% decrease from a year earlier, with the FY2025 full-year figure at $10.2 million, down 9.43% from the prior year.
• Total Liabilities declined to $7.5 million in Q1 2026 per TRVI's latest filing, from $10.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $20.9 million in Q2 2022 and bottomed at $5.9 million in Q2 2023.
• The 5-year median for Total Liabilities is $9.8 million (2025), against an average of $11.1 million.
• Across the five-year window, Total Liabilities slumped 71.75% in 2023 and soared 64.18% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $15.6 million in 2022, then sank by 55.93% to $6.9 million in 2023, then surged by 64.18% to $11.3 million in 2024, then fell by 9.43% to $10.2 million in 2025, then dropped by 26.64% to $7.5 million in 2026.
• Per Business Quant, the three latest TRVI Total Liabilities figures stand at $7.5 million (Q1 2026), $10.2 million (Q4 2025), and $9.6 million (Q3 2025).